A practical reference on 纯度测定: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-30 and is reviewed periodically as new material appears.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
纯度与身份确认依赖色谱与质谱的组合。反相高效液相色谱在 214 nm 紫外检测下分离主峰与相关杂质，给出纯度百分比与保留时间；电喷雾或基质辅助激光解吸电离质谱提供分子量，用于确认 N 端修饰是否完整。序列层面可通过肽图或氨基酸分析验证。含量测定常用紫外吸收法或氮元素分析，不同方法之间需要做交叉校验。
冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存，可维持较长时间的稳定。复溶后稳定性明显下降，溶液中的肽链易发生水解、氧化与聚集，通常需冷藏并在短期内用完。反复冻融会加速聚集与降解，建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率，需要按具体实验条件验证。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
== Research == Researchers are attempting to reproduce the biosynthetic pathway that produces morphine in genetically engineered yeast. In June 2015 the S-reticuline could be produced from sugar and R-reticuline could be converted to morphine, but the intermediate reaction could not be performed.
== Limitations == Several factors complicate simple correlation of obsidian hydration band thickness with absolute age. Temperature is known to speed up the hydration process. Thus, artifacts exposed to higher temperatures, for example by being at lower elevation, seem to hydrate faster. As well, obsidian chemistry, including the intrinsic water content, seems to affect the rate of hydration. Once an archeologist can control for the geochemical signature of the obsidian (e.g., the "source") and temperature (usually approximated using an "effective hydration temperature" or EHT coefficient), he or she may be able to date the artifact using the obsidian hydration technique. Water vapor pressure may also affect the rate of obsidian hydration. The reliability of the method based on Friedman's empirical age equation (x²=kt, where x is the thickness of the hydration rim, k is the diffusion coefficient, and t is the time) is questioned from several grounds regarding temperature dependence, square root of time and determination of diffusion rate per sample and per site, as part of some successful attempts on the procedure and applications. The SIMS-SS age calculation procedure is separated into two major steps. The first step concerns the calculation of a 3rd order fitting polynomial of the SIMS profile (eq. 1). The second stage regards the determination of the saturation layer, i.e. its depth and concentration.
By the time the comparatively youthful Mikhail Gorbachev became General Secretary in 1985, the Soviet economy was stagnant and faced a sharp fall in foreign currency earnings as a result of the downward slide in oil prices in the 1980s. These issues prompted Gorbachev to investigate measures to revive the ailing state. An ineffectual start led to the conclusion that deeper structural changes were necessary, and in June 1987 Gorbachev announced an agenda of economic reform called perestroika, or restructuring. Perestroika relaxed the production quota system, allowed cooperative ownership of small businesses and paved the way for foreign investment. These measures were intended to redirect the country's resources from costly Cold War military commitments to more productive areas in the civilian sector. Despite initial skepticism in the West, the new Soviet leader proved to be committed to reversing the Soviet Union's deteriorating economic condition instead of continuing the arms race with the West. Partly as a way to fight off internal opposition from party cliques to his reforms, Gorbachev simultaneously introduced glasnost, or openness, which increased freedom of the press and the transparency of state institutions. Glasnost was intended to reduce the corruption at the top of the Communist Party and moderate the abuse of power in the Central Committee. Glasnost also enabled increased contact between Soviet citizens and the Western world, particularly with the United States, contributing to the accelerating détente between the two nations.
Sources: en.wikipedia.org
Carbohydrate catabolism is the breakdown of carbohydrates into smaller units. Carbohydrates are usually taken into cells after they have been digested into monosaccharides such as glucose and fructose. Once inside, the major route of breakdown is glycolysis, in which glucose is converted into pyruvate. This process generates the energy-conveying molecule NADH from NAD+, and generates ATP from ADP for use in powering many processes within the cell. Pyruvate is an intermediate in several metabolic pathways, but the majority is converted to acetyl-CoA and fed into the citric acid cycle, which enables more ATP production by means of oxidative phosphorylation. This oxidation consumes molecular oxygen and releases water and the waste product carbon dioxide. When oxygen is lacking, or when pyruvate is temporarily produced faster than it can be consumed by the citric acid cycle (as in intense muscular exertion), pyruvate is converted to lactate by the enzyme lactate dehydrogenase, a process that also oxidizes NADH back to NAD+ for re-use in further glycolysis, allowing energy production to continue. The lactate is later converted back to pyruvate for ATP production where energy is needed, or back to glucose in the Cori cycle. An alternative route for glucose breakdown is the pentose phosphate pathway, which produces less energy but supports anabolism (biomolecule synthesis). This pathway reduces the coenzyme NADP+ to NADPH and produces pentose compounds such as ribose 5-phosphate for synthesis of many biomolecules such as nucleotides and aromatic amino acids.
In March 1997, the company patented this combination. The drug was approved in June 1997, by the FDA as Imodium Multi-Symptom Relief in the form of a chewable tablet. A caplet formulation was approved in November 2000. In November 1993, loperamide was launched as an orally disintegrating tablet based on Zydis technology. In 2013, loperamide was added to the WHO Model List of Essential Medicines.
Cangrelor is synthesized starting from 2-thiobarbituric acid and peracetyl-D-ribofuranose. The synthesis starts with the selective S-alkylation of 2-thiobarbituric acid, followed by nitration with nitric acid, leading to the nitrated dihydroxypyrimidine. Treatment with phosphorus oxychloride affords the corresponding dichloropyrimidine. Subsequently, the nitro group is reduced using iron as the reductant, yielding the aniline derivative. This is cyclized to the purine using triethyl orthoformate and hydrochloric acid. N,O-bis-(trimethylsilyl)acetamide is used to protect the anilinic nitrogen, allowing for the selective N9-alkylation of the compound with peracetyl-D-ribofuranose using trimethylsilyl triflate. The 5'-OH is converted to a phosphodichloridate using phosphorus oxychloride in triethyl phosphate as the solvent. This is converted to Cangrelor without isolation by reaction with dichloromethylenebis(phosphonic acid) and tributylamine as the base.
Sources: en.wikipedia.org
Native to cold temperate coastal areas of Japan, Korea, China, and Russia, in recent decades it has become established in temperate regions around the world, including New Zealand, the United States, Belgium, France, Great Britain, Spain, Italy, Argentina, Australia and Mexico. It was nominated one of the 100 worst invasive species in the world. Undaria is commonly initially introduced or recorded on artificial structures, where its r-selected growth strategy facilitates proliferation and spread to natural reef sites. Undaria populations make a significant but inconsistent contribution of food and habitat to intertidal and subtidal reefs. Undaria invasion can cause changes to native community composition at all trophic levels. As well as increasing primary productivity, it can reduce the abundance and diversity of understory algal assemblages, out-compete some native macroalgal species and affect the abundance and composition of associated epibionts and macrofauna, including gastropods, crabs, urchins and fish. Its dense congregation and capability to latch onto any hard surface has caused it to become a major cause of damage to aquaculture apparatus, decreasing efficiency of fishing industries by clogging underwater equipment and fouling boat hulls. Eradication of wakame within a localized area usually involves getting rid of the algae underwater, often via regular inspection of aquatic environments.
Wellcome established its second corporate brand, First Choice, with a product range of over 1,000 items. With prices at 20–30% less than competitive international brands, it is a well-known brand in Hong Kong. A HK$400 million investment, "Wellcome Fresh Food Centre" was opened in 1998, occupying an area of 161,000 sq. ft. In the 1990s, Wellcome Hong Kong to become the first to use the UPC system in Hong Kong supermarkets, offers a more efficient and more convenient payment services. According to the report of 2004–2008, Wellcome supermarkets and thus increase the number of branches. Wellcome introduced the "Vote For Your Favourite Brand" campaign in 2000 and soon opened a superstore at Tuen Mun Town Plaza. The Wellcome superstore introduced a new "one-stop" shopping service, embracing the concepts of both wet market and grocery shop under one roof. Wellcome also began its double refund offer with lowest price guarantee by doubling the difference back to customers. Wellcome unveiled its Stanley store in January 2003. It is the first supermarket located inside a 100-year-old historical building – the old Stanley Police Station. In 2014, Wellcome Taiwan was found to have used contaminated ingredients in its mushroom and minced pork seasonings, drawing it into the 2014 Taiwan food scandal. Wellcome Taiwan was acquired by Carrefour in 2020. While Wellcome Philippines locations were turned into Robinsons Easymart after Robinsons Retail purchased Rustan's Supercenters.
As well as these common law standards, the Fair Work Act 2009 section 117 requires a bare minimum of 1 week's notice before 1 year, 2 weeks' notice for 2 years, 3 weeks' notice for over 3 years, and 4 weeks' notice for over 5 years, but also an extra week for employees over 45 years old who have worked more than 2 years. Modern awards can and often do have higher standards, and so do collective agreements. The dominant view is that courts may find greater notice is warranted where the facts speak in favour, because statute's purpose is to create a floor of rights, not a ceiling, that common law may improve upon, not undercut. An employer may give pay in lieu of notice under section 117(2) and terminate the contract if this has been accepted by the employee. The one situation where notice is not required is where a party commits a serious breach of contract. In these cases, an employee can quit on the spot and claim damages, or an employer can dismiss the employee. According to Bartlett v ANZ Banking Group Ltd a serious breach of the employment contract can include deliberate disobedience of a lawful and reasonable order, breaching the duty of fidelity (e.g. by taking secret commissions), or serious incompetence. In this case, an ANZ Bank employee won damages for wrongful dismissal on appeal, measured by 4 months notice that his contract required, since ANZ could not prove he had actually engaged in misconduct of sending confidential information to a journalist at the Australian Financial Review, and the employer had an obligation to act reasonably.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.